Fulgent Genetic (NASDAQ:FLGT) released its quarterly earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.02 by ($0.04), Bloomberg Earnings reports. Fulgent Genetic had a negative return on equity of 0.02% and a negative net margin of 0.42%.

Shares of Fulgent Genetic (NASDAQ:FLGT) traded up $0.49 during mid-day trading on Monday, hitting $3.96. 44,669 shares of the stock traded hands, compared to its average volume of 43,213. Fulgent Genetic has a 12-month low of $3.40 and a 12-month high of $13.90.

TRADEMARK VIOLATION WARNING: “Fulgent Genetic (FLGT) Issues Quarterly Earnings Results” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/06/fulgent-genetic-flgt-issues-quarterly-earnings-results.html.

In other news, CFO Paul Kim sold 6,134 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $5.71, for a total transaction of $35,025.14. Following the sale, the chief financial officer now directly owns 388,602 shares in the company, valued at approximately $2,218,917.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 58.80% of the stock is owned by company insiders.

Several research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a research report on Monday, July 10th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $7.00 price target (down from $10.00) on shares of Fulgent Genetic in a research report on Wednesday, August 9th. ValuEngine upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a research report on Monday, October 2nd. Finally, Credit Suisse Group decreased their price target on shares of Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 8th.

Fulgent Genetic Company Profile

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with MarketBeat.com's FREE daily email newsletter.